ClinicaliQ Trial Snapshot
- Predicting Plaque Growth Using Blood Flow Stress Markers: A Proof-of-Concept Study — Recruiting • Non-phase study • Cardiology / Cardiovascular • NCT07864051.
- What is being tested: Blood flow stress markers (biomechanical indicators) are being evaluated as predictive tools to identify which coronary artery plaques will progress or rupture, rather than remain stable.
- Patient eligibility overview: The study includes patients with established coronary artery disease who have identifiable plaques; specific inclusion/exclusion criteria would determine suitability based on disease severity, imaging findings, and cardiac stability.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
Coronary artery disease occurs when fatty deposits (plaques) build up inside the arteries that supply blood to the heart. Some plaques remain stable, while others continue to grow or become more likely to rupture, which can lead to a heart attack. Identifying plaques that are at higher risk of progression could help doctors provide earlier and more personalized treatment. The purpose of this study is to determine whether combining information about blood flow within the coronary arteries with information about a person's biological response to blood flow can improve prediction…
Eligibility Snapshot
- : 1. Age ≥40 2. Stable angina, defined as typical symptoms with evidence of reversible ischemia in non-invasive test and/or documented obstructive coronary artery disease on coronary angiography (>70% stenosis of at least one major epicardial coronary artery or positive fractional flow reserve study)
- Patient that is willing and can provide written informed consent.
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.